Since 1949, lithium has been a mainstay for treating bipolar disorder (BD), a mental health condition marked by extreme mood swings. But scientists still don’t have a clear understanding of how the drug works, or why some patients respond better than others. Now, researchers reporting in ACS Central Science developed a method for imaging lithium in living cells, allowing them to discover […]
Mirtazapine, an antidepressant often used to treat agitation in patients with dementia, is ineffective, researchers reported on Oct. 21, 2021 in The Lancet. And the investigators found a potentially higher mortality with use of mirtazapine. “Our results indicate that mirtazapine, given with normal clinical care, is not clinically effective compared with placebo for the treatment of clinically significant agitation in […]
Menopausal hormone therapy (MHT — also known as hormone replacement therapy, HRT) does not appear to increase the risk of dementia onset, researchers reported on Sept. 29, 2021 in the BMJ/British Medical Journal. “We are happy to be able to report findings that will reassure women needing menopausal hormone therapy and facilitate conversations between doctors and patients about the safest […]
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the FDA has approved long-acting atypical antipsychotic Invega Hafyera (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to Invega Hafyera, patients must be adequately treated with Invega Sustenna (1-month paliperidone palmitate) for at least four months, or Invega Trinza (3-month paliperidone palmitate) […]
Recent Comments